AUTHOR=Simmonds Lucy , Lagrata Susie , Stubberud Anker , Cheema Sanjay , Tronvik Erling , Matharu Manjit , Kamourieh Salwa 

TITLE=An open-label observational study and meta-analysis of non-invasive vagus nerve stimulation in medically refractory chronic cluster headache

JOURNAL=Frontiers in Neurology

VOLUME=Volume 14 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1100426

DOI=10.3389/fneur.2023.1100426

ISSN=1664-2295

ABSTRACT=Background: Many patients with cluster headache (CH) are inadequately controlled by current treatment options. Non-invasive vagus nerve stimulation (nVNS) is reported to be effective in the management of CH though some studies suggest that it is ineffective.

Objective: To assess the safety and efficacy of nVNS in chronic cluster headache (CCH) patients. 

Method: We prospectively analysed data from 40 patients with refractory CCH in this open-label, observational study. Patients were seen in tertiary headache clinics at the National Hospital of Neurology and Neurosurgery and trained to use nVNS as preventative therapy. Patients reviewed at one month and then three-monthly from onset. The primary endpoint was number of patients achieving 50% reduction in attack frequency at 3 months. A meta-analysis of all published studies evaluating the efficacy of nVNS in CCH was also conducted. We searched MEDLINE for all studies investigating the use of nVNS as a preventive or adjunctive treatment for CCH with five or more participants. Combined mean difference and responder proportions with 95% confidence intervals (CI) were calculated from the included studies. 

Results:  17/40 patients (43%) achieved  50% reduction in attack frequency at 3 months. There was a significant reduction in monthly attack frequency from a baseline of 124 (+67) attacks to 79 (+63) attacks in month 3 (mean difference 44.7; 95% CI 25.1 to 64.3; p<0.001). In month 3, there was also a 1.2-point reduction in average severity from a baseline Verbal rating scale 8/10 (95% CI 0.5 to 1.9; p=0.001). Five studies were identified for meta-analysis. All open-label audits or observational studies, except one open-label randomised trial. A total of 137 patients were included in the meta-analysis. Meta-analysis of published reports showed a responder proportion of 0.35 (95% CI 0.12 to 0.62, n=137) and a mean reduction in headache frequency of 35.3 attacks per month (95% CI 11.0 to 59.5, n=108).

Conclusion: This study highlights the potential benefit of nVNS in CCH, with significant reductions in headache frequency and severity. To better characterise the effect, randomised sham-controlled trials are needed to confirm the beneficial response of VNS reported in some, but not all, open-label studies.